While many drugs are used exclusively for medical reasons, and others are used solely for recreation, some drugs are commonly used for both purposes. For example, cannabis, opioids, benzodiazepines, and stimulants are unique in many ways, but they share the fact that they are regularly consumed both medicinally and recreationally. However, it is not clear how the existence of recreational markets for substances affects moral judgments of their medical use. The current work shows that using a drug for medical reasons is viewed as less morally acceptable if other consumers use the same drug for recreation. This effect emerges because observers infer that medical users are less purely motivated by medical need. Accordingly, the negative effect of recreational drug use on moral judgments of its medical use is mitigated when patients do not have alternative treatment options. These findings have implications for patient stigmatization, drug marketing and lobbying, and policy and legislation designed to regulate the use of medical drugs with recreational benefits.
AmesDaniel L.FiskeSusan T. (2013), “Intentional Harms Are Worse, Even When They’re Not,” Psychological Science, 24 (9), 1755–62.
2.
AmesDaniel L.FiskeSusan T. (2015), “Perceived Intent Motivates People to Magnify Observed Harms,” Proceedings of the National Academy of Sciences, 112 (12), 3599–3605.
3.
AzcaratePatrick M.ZhangAlysandra J.KeyhaniSalomehSteigerwaldStaceyIshidaJulie H.CohenBeth E. (2020), “Medical Reasons for Cannabis Use, Forms of Use, and Patient Perception of Physician Attitudes Among the US Population,” Journal of General Internal Medicine, 35 (7), 1979–86.
4.
BaraszKateKimTamiEvangelidisIoannis (2019), “I Know Why You Voted for Trump: (Over) Inferring Motives Based on Choice,” Cognition, 188, 85–97.
5.
BatraRajeevAhtolaOlli T. (1991), “Measuring the Hedonic and Utilitarian Sources of Consumer Attitudes,” Marketing Letters, 2 (2), 159–70.
ChenQiushiLarochelleMarc R.WeaverDavis T.LietzAnna P.MuellerPeter P., Sarah Mercaldo, et al. (2019), “Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States,” JAMA Network Open, 2, 2, e187621.
CushmanFiery A. (2008), “Crime and Punishment: Distinguishing the Roles of Causal and Intentional Analyses in Moral Judgment,” Cognition, 108 (2), 353–80.
10.
DharRaviWertenbrochKlaus (2000), “Consumer Choice Between Hedonic and Utilitarian Goods,” Journal of Marketing Research, 37 (1), 60–71.
11.
Dinnin HuffAimeeHumphreysAshleeWilnerSarah J.S. (2021), “The Politicization of Objects: Meaning and Materiality in the US Cannabis Market,” Journal of Consumer Research, 48 (1), 22–50.
12.
DiounCyrus (2017), “Making the Medical Marijuana Market,” in The Architecture of Illegal Markets: Towards and Economic Sociology of Illegality in the Economy, BeckertJ.DeweyM., eds. Oxford, UK: Oxford University Press, 159–76.
13.
DiounCyrus (2018), “Negotiating Moral Boundaries: Social Movements and the Strategic (Re)definition of the Medical Cannabis Markets,” in Social Movements, Stakeholders, and Non-Market Strategy, BriscoeF.KingB.G.LeitzingerJ., eds. Bingley, UK: Emerald Publishing Limited, 53–82.
14.
DowellDeborahHaegerichTamara M.ChouRoger (2016), “CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016,” JAMA, 315 (15), 1624–45.
15.
DrazdowskiTessa K. (2016), “A Systematic Review of the Motivations for the Non-Medical Use of Prescription Drugs in Young Adults,” Drug and Alcohol Dependence, 162, 3–25.
16.
EckardtAndreKuettnerChristian (2003), “Treatment of Gustatory Sweating (Frey’s Syndrome) with Botulinum Toxin A,” Journal of the Sciences and Specialties of the Head and Neck, 25 (8), 624–8.
17.
FarberDavid (2021), The War on Drugs: A History. New York: NYU Press.
GoffmanErving (1963), Stigma: Notes on the Management of Spoiled Identity. New York: Prentice-Hall.
20.
GriffinDale W.RossLee (1991), “Subjective Construal, Social Inference, and Human Misunderstanding,” Advances in Experimental Social Psychology, 24, 319–59.
21.
GuglielmoSteveMalleBertram F. (2010), “Can Unintended Side-Effects be Intentional? Resolving a Controversy Over Intentionality and Morality,” Personality and Social Psychology Bulletin, 36 (12), 1635–47.
22.
HagertySerenaBaraszKate (2020), “Inequality in Socially Permissible Consumption,” Proceedings of the National Academy of Sciences, 117 (25), 14084–93.
23.
HayesAndrew F. (2013), “Conditional Process Modeling: Using Structural Equation Modeling to Examine Contingent Causal Processes,” in Structural Equation Modeling: A Second Course, HancockGregory R.MuellerRalph O., eds. Charlotte, NC: Information Age Publishing, 219–66.
24.
HechtJennifer (2007), The Happiness Myth: Why What We Think Is Right Is Wrong. New York: Harper Collins.
25.
Hincapie-CastilloJuan M.GoodinAmiePossingerMarie-ChristinUsmaniSilken A.VouriScott Martin (2020), “Changes in Opioid Use After Florida’s Restriction Law for Acute Pain Prescriptions,” JAMA Network Open, 3 (2), e200234.
26.
HirshmanElizabeth C.HolbrookMorris B. (1982), “The Experiential Aspects of Consumption,” Journal of Consumer Research, 9 (2), 132–40.
27.
HumphreysAshleeLatourKathryn A. (2013), “Framing the Game: Assessing the Impact of Cultural Representations on Consumer Perceptions of Legitimacy,” Journal of Consumer Research, 40 (4), 773–95.
28.
KeinanAnatKivetzRanNetzerOded (2016), “The Functional Alibi,” Journal of the Association for Consumer Research, 1 (4), 479–96.
29.
KhanUzmaDharRavi (2010), “Price-Framing Effects on the Purchase of Hedonic and Utilitarian Bundles,” Journal of Marketing Research, 47 (6), 1090–99.
30.
KhanUzmaDharRaviWertenbrochKlaus (2005), “Inside Consumption: Frontiers of Research on Consumer Motives, Goals, and Desires,” in A Behavioral Decision Theoretic Perspective on Hedonic and Utilitarian Choice, RatneshwarS.MickD.G., eds. Routledge, 166–87.
31.
KivetzRanZhengYuhuang (2006), “Determinants of Justification and Self-Control,” Journal of Experimental Psychology: General, 135 (4), 572.
32.
KlermanGerald L. (1972), “Psychotropic Hedonism vs. Pharmacological Calvinism,” Hastings Center Report, 1–3.
33.
KramerPeter D. (1993), Listening to Prozac. New York: Penguin Books.
34.
LuomaJason B.KohlenbergBarbara S.HayesSteven C.BuntingKaraRyeAlyssa K. (2008), “Reducing Self-Stigma in Substance Abuse Through Acceptance and Commitment Therapy: Model, Manual, Development, and Pilot Outcomes,” Addiction Research & Theory, 16 (2), 149–65.
35.
MalleBertram F.KnobeJoshua (1997), “The Folk Concept of Intentionality,” Journal of Experimental Social Psychology, 33 (2), 101–21.
36.
MartinErin L.StricklandJustin C.SchlienzNicolas J.MunsonJoelJacksonHeatherBonn-MillerMarcel O., et al. (2021), “Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial,” Frontiers in Psychiatry, https://pubmed.ncbi.nlm.nih.gov/34566726/.
NewmanGeorge E.CainDaylian M. (2014), “Tainted Altruism: When Doing Some Good Is Evaluated as Worse Than Doing No Good at All,” Psychological Science, 25 (3), 648–55.
40.
NicholsDavid E. (2004), “Hallucinogens,” Pharmacology & Therapeutics, 101 (2), 131–81.
O’CurrySuzanneStrahilevitzMichal (2001), “Probability and Mode of Acquisition Effects on Choices Between Hedonic and Utilitarian Options,” Marketing Letters, 12 (1), 37–49.
43.
PollanMichael (2021), This Is Your Brain on Plants. New York: Penguin Press.
44.
ReederGlenn D.KumarShamalaHesson-McInnisMatthew S.TrafimowDavid (2002), “Inferences About the Morality of an Aggressor: The Role of Perceived Motive,” Journal of Personality and Social Psychology, 83 (4), 789–803.
45.
ReuterPeterCaulkinsJonathan P. (1995), “Redefining the Goals of National Drug Policy: Recommendations from a Working Group,” American Journal of Public Health, 85 (8), 1059–63.
46.
RiisJasonSimmonsJoseph P.GoodwinGeoffrey P. (2008), “Preferences for Enhancement Pharmaceuticals: The Reluctance to Enhance Fundamental Traits,” Journal of Consumer Research, 35 (3), 495–508.
47.
ShohamMeyravMoldovanSaritSteinhartYael (2016), “Positively Useless: Irrelevant Negative Information Enhances Positive Impressions,” Journal of Consumer Psychology, 27 (2), 147–59.
48.
StrahilevitzMichalMyersJohn G. (1998), “Donations to Charity as Purchase Incentives: How Well They Work May Depend on What You Are Trying to Sell,” Journal of Consumer Research, 24 (4), 434–46.
49.
WhitingPenny F.WolffRobert F.DeshpandeSohanDi NisioMarcelloDuffyStevenHernandezAdrian V., et al. (2015), “Cannabinoids for Medical Use: A Systematic Review and Meta-Analysis,” JAMA, 313 (24), 2456–73.
50.
WilliamsElanor F.SteffelMary (2014), “Double Standards in the Use of Enhancing Products by Self and Others,” Journal of Consumer Research, 41 (2), 506–25.
51.
ZhangYingFishbachAyeletKruglanskiArie W. (2007), “The Dilution Model: How Additional Goals Undermine the Perceived Instrumentality of a Shared Path,” Journal of Personality and Social Psychology, 92 (3), 389–401.
